205 related articles for article (PubMed ID: 31433871)
1. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.
Sakae N; Josephs KA; Litvan I; Murray ME; Duara R; Uitti RJ; Wszolek ZK; Graff-Radford NR; Dickson DW
Mov Disord; 2019 Nov; 34(11):1655-1662. PubMed ID: 31433871
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
Ali F; Martin PR; Botha H; Ahlskog JE; Bower JH; Masumoto JY; Maraganore D; Hassan A; Eggers S; Boeve BF; Knopman DS; Drubach D; Petersen RC; Dunkley ED; van Gerpen J; Uitti R; Whitwell JL; Dickson DW; Josephs KA
Mov Disord; 2019 Aug; 34(8):1144-1153. PubMed ID: 30726566
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation.
Morino H; Kurashige T; Matsuda Y; Ono M; Sahara N; Miyasaka T; Soeda Y; Shimada H; Yamazaki Y; Takahashi T; Izumi Y; Ito H; Maruyama H; Higuchi M; Arihiro K; Suhara T; Takashima A; Kawakami H
Mov Disord Clin Pract; 2024 Jun; 11(6):720-727. PubMed ID: 38605589
[TBL] [Abstract][Full Text] [Related]
4. Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity.
Kaalund SS; Passamonti L; Allinson KSJ; Murley AG; Robbins TW; Spillantini MG; Rowe JB
Acta Neuropathol Commun; 2020 Feb; 8(1):11. PubMed ID: 32019605
[TBL] [Abstract][Full Text] [Related]
5. Protracted course progressive supranuclear palsy.
Couto B; Martinez-Valbuena I; Lee S; Alfradique-Dunham I; Perrin RJ; Perlmutter JS; Cruchaga C; Kim A; Visanji N; Sato C; Rogaeva E; Lang AE; Kovacs GG
Eur J Neurol; 2022 Aug; 29(8):2220-2231. PubMed ID: 35384155
[TBL] [Abstract][Full Text] [Related]
6. Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.
Orlandi F; Carlos AF; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Stephens YC; Schwarz CG; Senjem ML; Jack CR; Agosta F; Filippi M; Dickson DW; Josephs KA; Whitwell JL
Brain Commun; 2024; 6(2):fcae113. PubMed ID: 38660629
[TBL] [Abstract][Full Text] [Related]
7. [
Blazhenets G; Soleimani-Meigooni DN; Thomas W; Mundada N; Brendel M; Vento S; VandeVrede L; Heuer HW; Ljubenkov P; Rojas JC; Chen MK; Amuiri AN; Miller Z; Gorno-Tempini ML; Miller BL; Rosen HJ; Litvan I; Grossman M; Boeve B; Pantelyat A; Tartaglia MC; Irwin DJ; Dickerson BC; Baker SL; Boxer AL; Rabinovici GD; La Joie R
J Nucl Med; 2023 Dec; 64(12):1980-1989. PubMed ID: 37918868
[TBL] [Abstract][Full Text] [Related]
8. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype.
Koga S; Kouri N; Walton RL; Ebbert MTW; Josephs KA; Litvan I; Graff-Radford N; Ahlskog JE; Uitti RJ; van Gerpen JA; Boeve BF; Parks A; Ross OA; Dickson DW
Acta Neuropathol; 2018 Sep; 136(3):389-404. PubMed ID: 29926172
[TBL] [Abstract][Full Text] [Related]
9. PSP-FTD Complex: A Possible Variant of PSP.
Pradhan S; Tandon R
Am J Alzheimers Dis Other Demen; 2020; 35():1533317520922383. PubMed ID: 32648477
[TBL] [Abstract][Full Text] [Related]
10. Accurate digital quantification of tau pathology in progressive supranuclear palsy.
Pansuwan T; Quaegebeur A; Kaalund SS; Hidari E; Briggs M; Rowe JB; Rittman T
Acta Neuropathol Commun; 2023 Nov; 11(1):178. PubMed ID: 37946288
[TBL] [Abstract][Full Text] [Related]
11. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Respondek G; Kurz C; Arzberger T; Compta Y; Englund E; Ferguson LW; Gelpi E; Giese A; Irwin DJ; Meissner WG; Nilsson C; Pantelyat A; Rajput A; van Swieten JC; Troakes C; Josephs KA; Lang AE; Mollenhauer B; Müller U; Whitwell JL; Antonini A; Bhatia KP; Bordelon Y; Corvol JC; Colosimo C; Dodel R; Grossman M; Kassubek J; Krismer F; Levin J; Lorenzl S; Morris H; Nestor P; Oertel WH; Rabinovici GD; Rowe JB; van Eimeren T; Wenning GK; Boxer A; Golbe LI; Litvan I; Stamelou M; Höglinger GU;
Mov Disord; 2017 Jul; 32(7):995-1005. PubMed ID: 28500752
[TBL] [Abstract][Full Text] [Related]
12. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
Lozupone M; Dibello V; Daniele A; Solfrizzi V; Resta E; Panza F
Expert Opin Pharmacother; 2024 Apr; 25(5):571-584. PubMed ID: 38653731
[TBL] [Abstract][Full Text] [Related]
13. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
[TBL] [Abstract][Full Text] [Related]
14. Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies.
Coughlin DG; Hiniker A; Peterson C; Kim Y; Arezoumandan S; Giannini L; Pizzo D; Weintraub D; Siderowf A; Litvan I; Rissman RA; Galasko D; Hansen L; Trojanowski JQ; Lee E; Grossman M; Irwin D
J Neuropathol Exp Neurol; 2022 Nov; 81(12):953-964. PubMed ID: 36269086
[TBL] [Abstract][Full Text] [Related]
15. Correlation between clinical and neuropathological subtypes of progressive supranuclear palsy.
Koizumi R; Akagi A; Riku Y; Miyahara H; Sone J; Tanaka F; Yoshida M; Iwasaki Y
Parkinsonism Relat Disord; 2024 Mar; ():106076. PubMed ID: 38494398
[TBL] [Abstract][Full Text] [Related]
16. Delineation of early changes in cases with progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation.
Santpere G; Ferrer I
Brain Pathol; 2009 Apr; 19(2):177-87. PubMed ID: 18462470
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment in progressive supranuclear palsy is associated with tau burden.
Koga S; Parks A; Kasanuki K; Sanchez-Contreras M; Baker MC; Josephs KA; Ahlskog JE; Uitti RJ; Graff-Radford N; van Gerpen JA; Wszolek ZK; Rademakers R; Dickson DW
Mov Disord; 2017 Dec; 32(12):1772-1779. PubMed ID: 29082658
[TBL] [Abstract][Full Text] [Related]
18. Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.
Zhao Y; Tseng IC; Heyser CJ; Rockenstein E; Mante M; Adame A; Zheng Q; Huang T; Wang X; Arslan PE; Chakrabarty P; Wu C; Bu G; Mobley WC; Zhang YW; St George-Hyslop P; Masliah E; Fraser P; Xu H
Neuron; 2015 Sep; 87(5):963-75. PubMed ID: 26335643
[TBL] [Abstract][Full Text] [Related]
19. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies.
Zempel H
Cytoskeleton (Hoboken); 2024 Jan; 81(1):66-70. PubMed ID: 37795931
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
